Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer

Open access
Weischer, Maren, Nordestgaard, Børge G., Pharoah, Paul, Bolla, Manjeet K., Nevanlinna, Heli, van't Veer, Laura J., Garcia-Closas, Montserrat, Hopper, John L., Hall, Per, Andrulis, Irene L., Devilee, Peter, Fasching, Peter A., Anton-Culver, Hoda, Lambrechts, Diether, Hooning, Maartje, Cox, Angela, Giles, Graham G., Burwinkel, Barbara, Lindblom, Annika, Couch, Fergus J., Mannermaa, Arto, Grenaker Alnæs, Grethe, John, Esther M., Dörk, Thilo, Flyger, Henrik, Dunning, Alison M., Wang, Qin, Muranen, Taru A., van Hien, Richard, Figueroa, Jonine, Southey, Melissa C., Czene, Kamila, Knight, Julia A., Tollenaar, Rob A.E.M., Beckmann, Matthias W., Ziogas, Argyrios, Christiaens, Marie-Rose, Collée, Johanna Margriet, Reed, Malcolm W.R., Severi, Gianluca, Marme, Frederik, Margolin, Sara, Olson, Janet E., Kosma, Veli-Matti, Kristensen, Vessela N., Miron, Alexander, Bogdanova, Natalia, Shah, Mitul, Blomqvist, Carl, Broeks, Annegien, Sherman, Mark, Phillips, Kelly-Anne, Li, Jingmei, Liu, Jianjun, Glendon, Gord, Seynaeve, Caroline, Ekici, Arif B., Leunen, Karin, Kriege, Mieke, Cross, Simon S., Baglietto, Laura, Sohn, Christof, Wang, Xianshu, Kataja, Vesa, Børresen-Dale, Anne-Lise, Meyer, Andreas, Easton, Douglas F., Schmidt, Marjanka K., Bojesen, Stig E. · 2012 · Journal of Clinical Oncology

Abstract

Purpose: We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer–specific death, and risk of a second breast cancer in women with a first breast cancer. Patients and Methods: From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer–specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies. Results: CHEK2*1100delC heterozygosity was found in 459 patients (1.8%). In women with estrogen receptor–positive breast cancer, multifactorially adjusted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P = .004) for early death and 1.63 (95% CI, 1.24 to 2.15; log-rank P < .001) for breast cancer–specific death. In all women, hazard ratio for a second breast cancer was 2.77 (95% CI, 2.00 to 3.83; log-rank P < .001) increasing to 3.52 (95% CI, 2.35 to 5.27; log-rank P < .001) in women with estrogen receptor–positive first breast cancer only. Conclusion: Among women with estrogen receptor–positive breast cancer, CHEK2*1100delC heterozygosity was associated with a 1.4-fold risk of early death, a 1.6-fold risk of breast cancer–specific death, and a 3.5-fold risk of a second breast cancer. This is one of the few examples of a genetic factor that influences long-term prognosis being documented in an extensive series of women with breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.42.7336

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 181

Metadata

Authors
Weischer, M., Nordestgaard, B. G., Pharoah, P., Bolla, M. K., Nevanlinna, H., van't Veer, L. J., Garcia-Closas, M., Hopper, J. L., Hall, P., Andrulis, I. L., Devilee, P., Fasching, P. A., Anton-Culver, H., Lambrechts, D., Hooning, M., Cox, A., Giles, G. G., Burwinkel, B., Lindblom, A., Couch, F. J., Mannermaa, A., Grenaker Alnæs, G., John, E. M., Dörk, T., Flyger, H., Dunning, A. M., Wang, Q., Muranen, T. A., van Hien, R., Figueroa, J., Southey, M. C., Czene, K., Knight, J. A., Tollenaar, R. A. E. M., Beckmann, M. W., Ziogas, A., Christiaens, M.-R., Collée, J. M., Reed, M. W. R., Severi, G., Marme, F., Margolin, S., Olson, J. E., Kosma, V.-M., Kristensen, V. N., Miron, A., Bogdanova, N., Shah, M., Blomqvist, C., Broeks, A., Sherman, M., Phillips, K.-A., Li, J., Liu, J., Glendon, G., Seynaeve, C., Ekici, A. B., Leunen, K., Kriege, M., Cross, S. S., Baglietto, L., Sohn, C., Wang, X., Kataja, V., Børresen-Dale, A.-L., Meyer, A., Easton, D. F., Schmidt, M. K., & Bojesen, S. E.
Venue
Journal of Clinical Oncology
Published
2012-12-10
Volume
30
Issue
35
Pages
4308-4316
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2111742493
Cited by
181
References
3
FWCI
5.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2012.42.7336
The paper
Weischer, M., Nordestgaard, B. G., Pharoah, P., Bolla, M. K., Nevanlinna, H., van't Veer, L. J., Garcia-Closas, M., Hopper, J. L., Hall, P., Andrulis, I. L., Devilee, P., Fasching, P. A., Anton-Culver, H., Lambrechts, D., Hooning, M., Cox, A., Giles, G. G., Burwinkel, B., Lindblom, A., . . . Bojesen, S. E. (2012). CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.42.7336

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.